Comment
doi: 10.1038/nrclinonc.2016.121.
Epub 2016 Jul 26.
Haematological cancer: High-risk SMM - early action required
- PMID: 27458009
- DOI: 10.1038/nrclinonc.2016.121
Item in Clipboard
Comment
Haematological cancer: High-risk SMM - early action required
Nat Rev Clin Oncol.
2016 Sep.
No abstract available
Comment on
-
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.Lancet Oncol. 2016 Aug;17(8):1127-1136. doi: 10.1016/S1470-2045(16)30124-3. Epub 2016 Jul 9. Lancet Oncol. 2016. PMID: 27402145 Clinical Trial.
Similar articles
-
Haematological cancer: Improvements with daratumumab.Nat Rev Clin Oncol. 2016 Oct;13(10):592. doi: 10.1038/nrclinonc.2016.145. Epub 2016 Sep 7. Nat Rev Clin Oncol. 2016. PMID: 27600254 No abstract available.
-
Advances in the management of asymptomatic myeloma.Curr Opin Oncol. 2014 Nov;26(6):670-6. doi: 10.1097/CCO.0000000000000121. Curr Opin Oncol. 2014. PMID: 25210868 Review.
-
The road to treating smoldering multiple myeloma.Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S59-64. doi: 10.1016/j.clml.2014.04.012. Clin Lymphoma Myeloma Leuk. 2014. PMID: 25486957 Review.
-
Haematological cancer: Optimizing the treatment of multiple myeloma.Nat Rev Clin Oncol. 2014 Dec;11(12):686-8. doi: 10.1038/nrclinonc.2014.185. Epub 2014 Oct 28. Nat Rev Clin Oncol. 2014. PMID: 25348792 No abstract available.
-
Treatment of high-risk smoldering myeloma.Semin Oncol. 2016 Dec;43(6):695-696. doi: 10.1053/j.seminoncol.2016.11.005. Epub 2016 Nov 14. Semin Oncol. 2016. PMID: 28061988
References
-
- Lancet Oncol. 2016 Aug;17(8):1127-36 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
